Literature DB >> 27585376

Hidden in Plain Sight: Lung Impairment in Ischemic Heart Disease.

Surya P Bhatt1,2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27585376      PMCID： PMC5027214          DOI： 10.1164/rccm.201607-1521ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  13 in total

1.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

2.  Cardiovascular disease in COPD: a call for action.

Authors:  Surya P Bhatt; J Michael Wells; Mark T Dransfield
Journal:  Lancet Respir Med       Date:  2014-10       Impact factor: 30.700

3.  Undiagnosed airflow limitation in patients at cardiovascular risk.

Authors:  Emilie Bérard; Vanina Bongard; Nicolas Roche; Thierry Perez; Dany Brouquières; Dorota Taraszkiewicz; Stéphane Fievez; François Denis; Roger Escamilla; Jean Ferrières
Journal:  Arch Cardiovasc Dis       Date:  2011-11-18       Impact factor: 2.340

4.  Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes.

Authors:  Adam C Salisbury; Kimberly J Reid; John A Spertus
Journal:  Am J Cardiol       Date:  2007-01-09       Impact factor: 2.778

Review 5.  Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Wenjia Chen; Jamie Thomas; Mohsen Sadatsafavi; J Mark FitzGerald
Journal:  Lancet Respir Med       Date:  2015-07-22       Impact factor: 30.700

Review 6.  Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management.

Authors:  Gianluca Campo; Rita Pavasini; Michele Malagù; Susanna Mascetti; Simone Biscaglia; Claudio Ceconi; Alberto Papi; Marco Contoli
Journal:  Cardiovasc Drugs Ther       Date:  2015-04       Impact factor: 3.727

7.  Lung Function Abnormalities in Smokers with Ischemic Heart Disease.

Authors:  Frits M E Franssen; Joan B Soriano; Nicolas Roche; Paul H Bloomfield; Guy Brusselle; Leonardo M Fabbri; Francisco García-Rio; Mark T Kearney; Namhee Kwon; Bo Lundbäck; Klaus F Rabe; Alice Raillard; Hana Muellerova; John R Cockcroft
Journal:  Am J Respir Crit Care Med       Date:  2016-09-01       Impact factor: 21.405

8.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.

Authors:  Jørgen Vestbo; Julie A Anderson; Robert D Brook; Peter M A Calverley; Bartolome R Celli; Courtney Crim; Fernando Martinez; Julie Yates; David E Newby
Journal:  Lancet       Date:  2016-04-28       Impact factor: 79.321

9.  Impact of chronic obstructive pulmonary diseases on outcomes and hospital days after percutaneous coronary intervention.

Authors:  Jian Wei Zhang; Yu Jie Zhou; Qing Yang; Shi Wei Yang; Bin Nie; Xiao Han Xu
Journal:  Angiology       Date:  2012-08-31       Impact factor: 3.619

10.  Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan.

Authors:  Katsuya Onishi; Daisuke Yoshimoto; Gerry W Hagan; Paul W Jones
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-05-29
View more
  1 in total

1.  Involvement of c-Jun N-Terminal Kinase in TNF-α-Driven Remodeling.

Authors:  Irene M J Eurlings; Niki L Reynaert; Cheryl van de Wetering; Scott W Aesif; Evi M Mercken; Rafael de Cabo; Jos L van der Velden; Yvonne M Janssen-Heininger; Emiel F M Wouters; Mieke A Dentener
Journal:  Am J Respir Cell Mol Biol       Date:  2017-03       Impact factor: 6.914
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.